Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

Detalles Bibliográficos
Autores principales: Richardson, P. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S., Lonial, S., Laubach, J., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J., Doss, D., Zaki, M. H., Bensmaine, A., Herring, J., Li, Y., Watkins, L., Chen, M. S., Anderson, K. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887838/
https://www.ncbi.nlm.nih.gov/pubmed/30218008
http://dx.doi.org/10.1038/s41375-018-0235-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887838/
https://www.ncbi.nlm.nih.gov/pubmed/30218008
http://dx.doi.org/10.1038/s41375-018-0235-5

Ejemplares similares